Compare CHMI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | KPTI |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 94.6M |
| IPO Year | 2013 | 2013 |
| Metric | CHMI | KPTI |
|---|---|---|
| Price | $2.64 | $7.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.75 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 221.1K | 199.6K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $40,202,000.00 | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | $31.73 | $3.18 |
| P/E Ratio | $140.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.17 | $3.51 |
| 52 Week High | $3.68 | $12.45 |
| Indicator | CHMI | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 60.74 |
| Support Level | $2.47 | $5.99 |
| Resistance Level | $2.62 | $7.48 |
| Average True Range (ATR) | 0.06 | 0.53 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 92.96 | 72.48 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.